Outputs (4)

Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets (2020)
Journal Article
Aburima, A., Berger, M., Spurgeon, B. E., Webb, B. A., Wraith, K. S., Febbraio, M., Poole, A. W., & Naseem, K. M. (2021). Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets. Blood, 137(5), 678-689. https://doi.org/10.1182/blood.2020005382

Thrombospondin-1 (TSP-1) is released by platelets upon activation and can increase platelet activation, but its role in hemostasis in vivo is unclear. We show that TSP-1 is a critical mediator of hemostasis that promotes platelet activation by modula... Read More about Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.

Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A. (2019)
Journal Article
Berger, M., Raslan, Z., Aburima, A., Magwenzi, S., Wraith, K. S., Spurgeon, B. E., Hindle, M. S., Law, R., Febbraio, M., & Naseem, K. M. (2020). Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A. Haematologica, 105(3), 808-819. https://doi.org/10.3324/haematol.2018.213348

©2020 Ferrata Storti Foundation Prostacyclin (PGI2) controls platelet activation and thrombosis through a cyclic adenosine monophosphate (cAMP) signaling cascade. However, in patients with cardiovascular diseases this protective mechanism fails for r... Read More about Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A..

Platelet function following induced hypoglycaemia in type 2 diabetes (2018)
Journal Article
Kahal, H., Aburima, A., Spurgeon, B., Wraith, K. S., Rigby, A. S., Sathyapalan, T., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2018). Platelet function following induced hypoglycaemia in type 2 diabetes. Diabetes & metabolism, 44(5), 431-436. https://doi.org/10.1016/j.diabet.2018.04.004

Aim
Strict glycaemic control has been associated with an increased mortality rate in subjects with type 2 diabetes (T2DM). Here we examined platelet function immediately and 24 hours following induced hypoglycaemia in people with type 2 diabetes comp... Read More about Platelet function following induced hypoglycaemia in type 2 diabetes.

Oxidized LDL activates blood platelets through CD36/NOX2–mediated inhibition of the cGMP/protein kinase G signaling cascade (2015)
Journal Article
Magwenzi, S., Woodward, C., Wraith, K. S., Aburima, A., Raslan, Z., Jones, H., McNeil, C., Wheatcroft, S., Yuldasheva, N., Febbriao, M., Kearney, M., & Naseem, K. M. (2015). Oxidized LDL activates blood platelets through CD36/NOX2–mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood, 125(17), 2693-2703. https://doi.org/10.1182/blood-2014-05-574491

Oxidized low-density lipoprotein (oxLDL) promotes unregulated platelet activation in dyslipidemic disorders. Although oxLDL stimulates activatory signaling, it is unclear how these events drive accelerated thrombosis. Here, we describe a mechanism fo... Read More about Oxidized LDL activates blood platelets through CD36/NOX2–mediated inhibition of the cGMP/protein kinase G signaling cascade.